DERBY, UK, 12-Dec-2016 — /EuropaWire/ — The Rolls-Royce Trent 1000 TEN has powered a Boeing 787 Dreamliner flight for the first time.
The flight, which took off and landed at Boeing Field, Seattle, Washington, US, marks the latest phase in the engine’s development programme.
The Trent 1000 TEN has also been selected to power the first test flight of the Boeing 787-10 version of the Dreamliner next year. This means the Trent 1000 will have powered the first flight of every version of the 787.
Trent 1000 Programme Director Gary Moore said: “Our first Trent 1000 TEN flight on the 787 Dreamliner is another great milestone for our programme. I want to thank everyone at Boeing and Rolls-Royce who have worked hard to make this flight happen. In addition, our selection to power the first flight of the 787-10 is a great honour, and reflects our commitment to supporting this aircraft as it continues to evolve.”
The Trent 1000 TEN has already powered tests earlier this year on the Rolls-Royce Flying Test Bed aircraft, a Boeing 747, at Tucson, Arizona, US.
The Trent 1000 TEN (Thrust, Efficiency and New Technology) will power all variants of the Boeing 787 Dreamliner family. The engine draws on technologies from the Rolls-Royce Trent XWB engine and Advance engine programme, delivering thrust and efficiency improvements.
The Trent 1000 powered the first 787-8 entry into service in 2011 and the first 787-9 into service in 2014.
For high-res images please see here: https://www.flickr.com/photos/rolls-royceplc
For b-roll engine footage see here: https://vimeo.com/194802172
https://vimeo.com/194802649
About Rolls-Royce Holdings plc
SOURCE: Rolls-Royce plc
PRESS CONTACT
Richard Wray
DIRECTOR OF EXTERNAL COMMUNICATIONS
Tel: +44 (0)2072279163
Mobile: +44 (0)7974918416
Sarah Roberts
EXTERNAL COMMUNICATIONS MANAGER
Mobile: +44 (0)7968906469
(IN BRIEF) Eurex, on April 29, 2024, introduced a new Green Bond Basket within its…
(IN BRIEF) Last Friday, NMB Bank Plc celebrated the listing of its dual-currency sustainability bond,…
(IN BRIEF) CapMan Nordic Infrastructure II fund has reached its final closing at over €375…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the…
(IN BRIEF) Ørsted, a global leader in renewable energy, is divesting its French onshore operations…